HGH Fragment 176-191 Research Guide: Lipolytic C-Terminal Fragment
HGH Fragment 176-191 is the lipolytic C-terminal region of human growth hormone, isolated from its growth-promoting activity.
What is HGH Fragment 176-191?
The 16-amino-acid C-terminal fragment of human growth hormone, first characterized by Frank Ng at Monash University in the 1990s as part of a program to isolate hGH's fat-metabolism effects from its anabolic and diabetogenic properties.
Sourcing & purity
Research-grade material should be ≥99% pure by HPLC with peptide content confirmed via mass spectrometry. Redline Bio material ships with batch documentation; independent third-party COAs are published on the lab reports page as testing returns.
Compliance reminder
Sold and distributed for laboratory research use only. Not approved by the FDA for human consumption, diagnosis, treatment, or cure of any disease. Researchers are responsible for compliance with all applicable institutional, state, and federal regulations.
Frequently asked questions
What is HGH Fragment 176-191?
It is a synthetic peptide corresponding to residues 176–191 of the C-terminal region of human growth hormone. This fragment retains hGH's lipolytic activity but has been dissociated from its growth-promoting and insulin-antagonist properties.
Mechanism?
The fragment stimulates β3-adrenergic-receptor-mediated lipolysis in adipocytes, driving triglyceride breakdown and fatty acid release. Unlike full hGH, it does not activate IGF-1 signaling or impair glucose tolerance.
How does it differ from AOD-9604?
AOD-9604 is a modified version of this same fragment with a tyrosine added at the N-terminus for enhanced stability. Mechanism and target are the same; AOD-9604 has better pharmacokinetic characterization in published trials.